Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1838)	7/13/2007 2:21:32 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 3722

Bernard; As I see your post and look at the charts you submit, I can't help but wonder what it is you are looking at when making a judgement based on technicals. Seems to me there are just a ton of technical things to look at in a chart and unless we know what you are looking at - and since they are not identified on the charts - anyone else is commenting on the blind. Sooooo, can you tell me what you are looking at on the charts you submit? I think technicals can identify moving stocks - and use P&F a lot, but of course those are not the charts you are providing. Thanks Bernard - interesting topic! steve

To: Jibacoa who wrote (1838)	1/15/2008 2:20:24 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MITI Is trying to revert yesterday's dip & climb back above $2.<g> bigcharts.marketwatch.com Its 3rdQ results were good with 20% better revenues & it trimmed its loss by 75%. At the ASH meeting in Dec, it presented new data from an ongoing PI, showing potent single-agent activity of its MT103 in patients with late-stage NHL. Since the drug is been developed in combination AZN's subsidiary, Medimmune, it is also known as MEDI-538. It is a recombinant T-cell engaging antibody targeting the CD19 antigen, which is uniquely expressed on B-cells. The insiders reportedly hold > 30%. Th short ratio came down > 30% in the last month.<g> bigcharts.marketwatch.com Bernard